The Kratom Supply Chain, in a Manufacturer’s Own Words

The document lawmakers should read

When lawmakers hear about kratom, they are often presented with two supposedly separate markets: natural kratom leaf on one side, and chemically modified 7-hydroxymitragynine (7-OH) products on the other. A manufacturer's own federal filing shows why that distinction can conceal an essential part of the story.

On November 20, 2025, Shaman Botanicals, LLC submitted a “catch-up” New Dietary Ingredient Notification (NDIN) to the U.S. Food and Drug Administration for 7-OH. The company sought to support the marketing of dietary supplements containing 7.5 milligrams of 7-OH per tablet, with labeling recommending no more than two tablets in 24 hours. It also asserted that 7-OH should not be considered a new dietary ingredient, while submitting the notification as a precaution.^[1]

Primary-source document: 20-page publicly released file containing the original notification, FDA's information request and the manufacturer's redacted amendment.

FDA's own words: manufactured from kratom

The original submission describes 7-OH as a “concentrate, metabolite, constituent, and/or extract” of kratom, Mitragyna speciosa. That language is broad. But FDA's subsequent correspondence is more direct.

FDA did not simply accept the submission as complete. It demanded a description of raw materials, ingredient verification, manufacturing specifications, analytical methods and a complete manufacturing narrative and flowchart. FDA explained that the missing information was necessary to establish the identity of the ingredient and finished supplements.^[1]

The documented point is unmistakable: this manufacturer represented a kratom-based source for its 7-OH, and FDA expressly recognized that representation in writing.

What the public cannot see

On December 12, Shaman Botanicals responded to FDA's request. The released amendment contains extensive blacked-out passages under FOIA Exemption 4, which protects certain confidential commercial information. Among the concealed material are answers addressing raw ingredients, the manufacturing process and product specifications.

The visible record therefore does not prove that Shaman started with raw kratom leaf rather than a purchased kratom extract or isolated mitragynine. Nor does it reveal the specific chemical transformation used in this company's production.

That limitation does not erase what is visible. The original filing identifies kratom as the botanical source, and FDA explicitly says the company's 7-OH is manufactured from kratom. The precise route remains concealed; the declared upstream relationship does not.

Why the starting material matters

Kratom leaf contains mitragynine, its principal alkaloid. Mitragynine can be isolated from kratom-derived material and chemically converted into 7-OH. That is one documented pathway linking the botanical market to concentrated downstream products. The Shaman filing is evidence of a manufacturer describing its own ingredient as kratom-derived; it is not, by itself, proof of which conversion process Shaman used.

The regulatory question is larger than the label on the finished tablet. If the plant or its extracted alkaloids supply the feedstock for chemical modification, a policy that addresses only the finished 7-OH product may leave the upstream supply chain untouched.

That is not a claim that ordinary kratom powder and concentrated 7-OH tablets are chemically identical. They are not. It is a demand that lawmakers examine where the downstream product comes from, rather than stopping the inquiry at what the finished package calls itself.

For additional chemical and manufacturing evidence, see Where High-Potency Kratom Products Come From.

The omission in the lobbying argument

Kratom-industry advocates have urged lawmakers to distinguish “natural kratom” from products described as synthetic or semi-synthetic 7-OH. There is a legitimate chemical distinction between an unmodified leaf and a chemically transformed alkaloid. But the distinction becomes incomplete when the discussion ends there.

What is too often left unexplained is the upstream question: Can the natural kratom market provide the starting alkaloids used to manufacture the products the industry asks lawmakers to treat as a separate problem?

Here, a commercial manufacturer supplied a relevant answer in a federal filing. Its 7-OH was represented as manufactured from kratom. FDA repeated that representation and demanded the manufacturing records.

The public record does not establish that every kratom-industry lobbyist knew of this particular filing or deliberately withheld it. It does establish that a categorical division between botanical kratom and kratom-derived 7-OH leaves out a documented manufacturing relationship. Lawmakers should require advocates who draw that division to address the relationship directly.

Calling the finished product semi-synthetic does not answer where its starting material came from.

The warning labels are revealing, too

The notification describes labeling that acknowledges the products contain psychoactive alkaloids interacting with the opioid system. Its warnings discuss dependence, addiction, withdrawal, medication interactions, impairment and the potential presence of mitragynine pseudoindoxyl alongside mitragynine and 7-OH.^[1]

Those statements are part of the company's submitted labeling, not independent FDA findings. They are nonetheless significant because they show what the manufacturer itself placed before federal regulators while arguing that its product could be marketed as a dietary supplement.

Questions lawmakers should put on the record

1. What percentage of commercial 7-OH production begins with kratom leaf, kratom extracts or kratom-derived mitragynine?
2. When industry representatives distinguish “natural kratom” from 7-OH, do they disclose the role of kratom-derived starting materials?
3. What evidence establishes the source and manufacturing process for products sold as 7-OH?
4. If legislation restricts finished 7-OH but leaves kratom-derived precursor materials unrestricted, what prevents those materials from continuing to supply downstream manufacturing?
5. What manufacturing and laboratory records should regulators obtain before accepting claims that a product is separate from the botanical kratom supply chain?

These are questions of evidence, not terminology. A legislature cannot fully evaluate a proposed distinction between products without examining the commercial supply chain connecting them.

The point for lawmakers

Shaman Botanicals asked FDA to consider a 7-OH dietary ingredient. In doing so, it described a kratom-derived product. FDA responded by stating that the company's 7-OH was manufactured from kratom and demanded the manufacturing details. The public can read the first two facts. The detailed production information remains redacted.

Lawmakers need not speculate about the missing pages to recognize the significance of those that are visible.

The debate should not be confined to whether a tablet is “natural” or “synthetic.” It should include the botanical and chemical supply chain that makes the tablet possible.

Primary source and further reading

1. Shaman Botanicals, LLC. “Catch-up New Dietary Ingredient Notification for 7-Hydroxymitragynine,” November 20, 2025; FDA information request, December 3, 2025; Shaman amendment, December 12, 2025. Read the 20-page document (PDF). Relevant pages: 1–3 (identity, dosage and labels), 12 (FDA manufacturing-source statement), 14–19 (redacted amendment).
2. Global Kratom Policy Review. Where High-Potency Kratom Products Come From. Additional published research, patent literature and manufacturing evidence.

Source distinction: the manufacturer's statements and FDA's characterization are documented in the cited correspondence. The particular raw material form, proprietary manufacturing steps and chemistry used by Shaman are not established by the public, redacted record.